PP
ANTH

Paloma Partners’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Paloma Partners’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-37,200
Closed -$60K – 2656
2017
Q2 		$60K Buy
+37,200
New +$83.4K ﹤0.01% 2105
2017
Q1 		– Sell
-2,197
Closed -$11K – 2390
2016
Q4 		$11K Buy
+2,197
New +$38K ﹤0.01% 1944

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Paloma Partners's ANTH Position: Q3 2017 in Review

Paloma Partners sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q3 2017, closing a stake of 37,200 shares — an estimated $60K sold.

Paloma Partners first reported a position in ANTH in Q4 2016 and held it in 2 quarters. The position peaked at $60K in Q2 2017. 35 funds tracked by Wall St. Rank hold ANTH as of Q3 2017.

  • Paloma Partners reported no remaining Anthera Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Paloma Partners sold 37,200 Anthera Pharmaceuticals, Inc. shares in Q3 2017, an estimated $60K.
  • Paloma Partners first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
  • Paloma Partners's Anthera Pharmaceuticals, Inc. position peaked at $60K in Q2 2017.
  • 35 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.